Türkçesi için Tıklayınız.
Thanks to immuno-oncology therapy for cancer treatments
Immuno-oncology theraphy has survival advantage four times more than chemotherapy in metastatic or high level cancer forms.
One doctor of Medipol Mega University Hospital Medical Oncology Department, Prof. Dr. Ahmet Bilici stated that patients can live 3 years by using chemotheraphy in cancer treatment; but patients can live 13 years by using immunooncology therapy in cancer threatment.
The IASLC 2019 World Lung Cancer Congress, organized by the International Lung Cancer Working Group, was held on 7-10 September 2019 in Barcelona. Oncology, chest diseases specialists and doctors from other branches of the cancer treatment process from all over the world participated in the Congressum and explained the clinical studies of cancer.
Immuno-Oncology Therapy Extends Life of Cancer Patients
Innovative approaches in lung cancer and treatment facilities are presented at the congress. In addition, findings about immunooncology therapy practices for 5 years on metastatic or advanced non-small cell lung cancer were presented in the congress.
It contributes more to the survival rate of advanced cancer patients who have previously undergone chemotherapy.
Professor Dr. Ahmet Bilici said that “In patients treated with immuno-oncology in metastatic non-small cell lung cancer, when we look at the results, we can find that 5-year survival rates in patients receiving chemotherapy 3 percent, while this rate was 13 percent in immuno-oncological treatment group."
Among surviving patients at 5 years, the rate of those who continue to use immuno-oncology therapy is 36 percent.
"In addition, when we compare immuno-oncological treatments with chemotherapies, we can say that they can be applied more easily in terms of side effects. ”